Nephros

Nephros EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Nephros (NEPH) as of Nov 4, 2026 is 34.23. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 238.27 — a change of -85.63% (lower).

EV/EBITDA

34.23

YoY

-85.63%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Nephros is 2025 34.23 . EV/EBITDA (Enterprise Value to EBITDA) of Nephros was 2024 238.27 . It decreases by -85.63% lower compared to the previous year.

The Nephros EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-13.29 USD
Jan 1, 2019
-13.89 USD
Jan 1, 2020
-8.85 USD
Jan 1, 2021
-12.48 USD
Jan 1, 2022
-10.12 USD
Jan 1, 2023
-30.74 USD
Jan 1, 2024
238.27 USD
Jan 1, 2025
34.23 USD
The Nephros EV/EBITDA history
YEAREV/EBITDAYoY
34.23-85.63%
238.27-875.13%
-30.74+203.81%
-10.12-18.94%
-12.48+41.06%
-8.85-36.31%
-13.89+4.54%
-13.29-35.86%
-20.72+23.80%
-16.74+27.00%
-13.18-23.67%
-17.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nephros Stock analysis

What does Nephros do? Nephros, Inc. generates revenue through its Water Filtration and Renal Products segments. The Water Filtration segment sells high-performance water purification filters for hospitals, healthcare facilities, dialysis centers, commercial facilities, military, and outdoor recreation markets. The Renal Products segment offers a second-generation hemodiafiltration system for end-stage renal disease patients. Products include ultrafiltration systems used in medical and commercial applications, with subsidiaries Biocon 1, LLC, Aether Water Systems, LLC, and Specialty Renal Products, Inc. supporting sales and development. The company's water filtration products are sold to hospitals, dialysis centers, and commercial facilities, while the hemodiafiltration system targets healthcare providers treating ESRD patients. Subsidiaries handle specialized development and distribution, ensuring market coverage across medical and commercial sectors. Revenue streams are derived from both segments, with products serving healthcare infrastructure and renal treatment needs. Nephros, Inc. focuses on medical device solutions for renal disease and water purification, leveraging its subsidiaries to expand market reach. The Water Filtration segment serves healthcare and commercial clients, while the Renal Products segment addresses ESRD treatment through advanced hemodiafiltration technology, creating a diversified revenue model. Nephros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nephros stock

EV/EBITDA (Enterprise Value to EBITDA) of Nephros is 34.23 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Nephros changed from 238.27 to 34.23, representing a -85.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Nephros since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Nephros with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Nephros

All Key Metrics — Nephros